Log in

NASDAQ:NXTCNextCure Stock Price, Forecast & News

$34.54
-0.34 (-0.97 %)
(As of 05/27/2020 04:00 PM ET)
Add
Compare
Today's Range
$31.30
Now: $34.54
$35.29
50-Day Range
$32.76
MA: $35.84
$40.20
52-Week Range
$13.86
Now: $34.54
$109.00
Volume217,035 shs
Average Volume233,515 shs
Market Capitalization$950.44 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for NextCure Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.68 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NXTC
CUSIPN/A
CIKN/A
Phone240-399-4900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.35 million
Book Value$12.06 per share

Profitability

Net Income$-33,740,000.00

Miscellaneous

EmployeesN/A
Market Cap$950.44 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.

NextCure (NASDAQ:NXTC) Frequently Asked Questions

How has NextCure's stock been impacted by COVID-19 (Coronavirus)?

NextCure's stock was trading at $38.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NXTC stock has decreased by 9.6% and is now trading at $34.54. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of NextCure?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NextCure.

When is NextCure's next earnings date?

NextCure is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for NextCure.

How were NextCure's earnings last quarter?

NextCure Inc (NASDAQ:NXTC) posted its quarterly earnings results on Thursday, May, 7th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of ($0.44) by $0.77. The business earned $22.38 million during the quarter, compared to analyst estimates of $1.30 million. NextCure had a negative return on equity of 7.12% and a negative net margin of 65.22%. View NextCure's earnings history.

What price target have analysts set for NXTC?

9 brokerages have issued 1 year price targets for NextCure's shares. Their forecasts range from $44.00 to $87.00. On average, they expect NextCure's share price to reach $65.11 in the next year. This suggests a possible upside of 88.5% from the stock's current price. View analysts' price targets for NextCure.

Has NextCure been receiving favorable news coverage?

News headlines about NXTC stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NextCure earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutNextCure.

Are investors shorting NextCure?

NextCure saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,260,000 shares, an increase of 7.7% from the April 30th total of 1,170,000 shares. Based on an average daily volume of 224,300 shares, the short-interest ratio is currently 5.6 days. Currently, 7.9% of the shares of the stock are sold short. View NextCure's Current Options Chain.

Who are some of NextCure's key competitors?

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Amgen (AMGN), Alibaba Group (BABA), CVS Health (CVS), Dicerna Pharmaceuticals (DRNA), UnitedHealth Group (UNH), Honeywell International (HON), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T) and Arena Pharmaceuticals (ARNA).

When did NextCure IPO?

(NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

Who are NextCure's major shareholders?

NextCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Lord Abbett & CO. LLC (7.77%), Canaan Partners X LLC (7.37%), Alliancebernstein L.P. (4.56%), BlackRock Inc. (4.04%), Cormorant Asset Management LP (2.70%) and ArrowMark Colorado Holdings LLC (2.66%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View institutional ownership trends for NextCure.

Which institutional investors are selling NextCure stock?

NXTC stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Canaan Partners X LLC, Wellington Management Group LLP, ArrowMark Colorado Holdings LLC, Morgan Stanley, EAM Global Investors LLC, EAM Investors LLC, and JPMorgan Chase & Co.. View insider buying and selling activity for NextCure.

Which institutional investors are buying NextCure stock?

NXTC stock was purchased by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Jennison Associates LLC, Alliancebernstein L.P., State Street Corp, Geode Capital Management LLC, Trexquant Investment LP, HarbourVest Partners LLC, and BlackRock Inc.. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu, and X LP Canaan. View insider buying and selling activity for NextCure.

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $34.54.

How big of a company is NextCure?

NextCure has a market capitalization of $950.44 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

What is NextCure's official website?

The official website for NextCure is www.nextcure.com.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.